RU2311408C2 - Производные аминотетралина в качестве антагонистов мускаринового рецептора - Google Patents
Производные аминотетралина в качестве антагонистов мускаринового рецептора Download PDFInfo
- Publication number
- RU2311408C2 RU2311408C2 RU2004120558/04A RU2004120558A RU2311408C2 RU 2311408 C2 RU2311408 C2 RU 2311408C2 RU 2004120558/04 A RU2004120558/04 A RU 2004120558/04A RU 2004120558 A RU2004120558 A RU 2004120558A RU 2311408 C2 RU2311408 C2 RU 2311408C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- formula
- compounds
- group
- piperidin
- Prior art date
Links
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title claims abstract 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 24
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 5
- 125000002541 furyl group Chemical group 0.000 claims abstract 5
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 5
- 125000001544 thienyl group Chemical group 0.000 claims abstract 5
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims abstract 4
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract 4
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 4
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 210000002460 smooth muscle Anatomy 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 208000029578 Muscle disease Diseases 0.000 claims abstract 2
- 208000021642 Muscular disease Diseases 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- -1 cyano, amino Chemical group 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- NKHBRICCVXXZEY-UHFFFAOYSA-N 1-[4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]ethanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C1CCN(C(C)=O)CC1 NKHBRICCVXXZEY-UHFFFAOYSA-N 0.000 claims 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 claims 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 claims 1
- QAHIMRFXRHCIOG-UHFFFAOYSA-N [4-[(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCNCC1 QAHIMRFXRHCIOG-UHFFFAOYSA-N 0.000 claims 1
- DQKILXZDCFYBEZ-UHFFFAOYSA-N [4-[(6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)C1CCNCC1 DQKILXZDCFYBEZ-UHFFFAOYSA-N 0.000 claims 1
- VXFXLZREKZSIKG-UHFFFAOYSA-N [4-[(7-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound C1CC2=CC=C(Br)C=C2CC1N(CCC)C(CC1)CCN1C(=O)C1CCNCC1 VXFXLZREKZSIKG-UHFFFAOYSA-N 0.000 claims 1
- FEDSKDMGCCFDLP-UHFFFAOYSA-N [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCN(C)CC1 FEDSKDMGCCFDLP-UHFFFAOYSA-N 0.000 claims 1
- UVJLNVPSONWHRV-UHFFFAOYSA-N [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]piperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1CC2=CC=C(OC)C=C2CC1N(CCC)C(CC1)CCN1C(=O)N1CCOCC1 UVJLNVPSONWHRV-UHFFFAOYSA-N 0.000 claims 1
- MQBCOLWDJUCQRW-IBGZPJMESA-N [4-[3-[(2R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]propylamino]piperidin-1-yl]-piperidin-4-ylmethanone Chemical compound COC1=CC=C2CC[C@@H](CC2=C1)CCCNC1CCN(CC1)C(=O)C1CCNCC1 MQBCOLWDJUCQRW-IBGZPJMESA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33667501P | 2001-12-03 | 2001-12-03 | |
| US60/336,675 | 2001-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004120558A RU2004120558A (ru) | 2005-07-20 |
| RU2311408C2 true RU2311408C2 (ru) | 2007-11-27 |
Family
ID=23317154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004120558/04A RU2311408C2 (ru) | 2001-12-03 | 2002-11-25 | Производные аминотетралина в качестве антагонистов мускаринового рецептора |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6635658B2 (enExample) |
| EP (1) | EP1453806B1 (enExample) |
| JP (1) | JP4322675B2 (enExample) |
| KR (1) | KR100668231B1 (enExample) |
| CN (1) | CN100358870C (enExample) |
| AR (1) | AR037611A1 (enExample) |
| AT (1) | ATE381541T1 (enExample) |
| AU (1) | AU2002352124A1 (enExample) |
| BR (1) | BR0214649A (enExample) |
| CA (1) | CA2469055C (enExample) |
| DE (1) | DE60224221T2 (enExample) |
| ES (1) | ES2297029T3 (enExample) |
| MX (1) | MXPA04005313A (enExample) |
| PL (1) | PL370799A1 (enExample) |
| RU (1) | RU2311408C2 (enExample) |
| WO (1) | WO2003048125A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
| EA200500173A1 (ru) | 2002-07-08 | 2005-08-25 | Рэнбакси Лабораториз Лимитед | Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов |
| US7488748B2 (en) * | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| WO2004089900A1 (en) | 2003-04-11 | 2004-10-21 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| EP1781300A1 (en) | 2004-07-16 | 2007-05-09 | ProteoSys AG | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| WO2006035303A1 (en) * | 2004-09-29 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006054162A1 (en) * | 2004-11-19 | 2006-05-26 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
| EP1828126A1 (en) * | 2004-12-15 | 2007-09-05 | Ranbaxy Laboratories Limited | Acid addition salts of muscarinic receptor antagonists |
| US9198897B2 (en) * | 2005-01-19 | 2015-12-01 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
| MX2007011453A (es) * | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| US20080319043A1 (en) * | 2005-05-03 | 2008-12-25 | Mohammad Salman | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists |
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| NZ716598A (en) * | 2012-11-20 | 2017-02-24 | Merial Inc | Anthelmintic compounds and compositions and method of using thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000412A1 (en) * | 1996-07-01 | 1998-01-08 | Schering Corporation | Muscarinic antagonists |
| WO1998001425A1 (en) * | 1996-07-10 | 1998-01-15 | Schering Corporation | 1,4-di-sustituted piperidines as muscarinic antagonists |
| RU98119276A (ru) * | 1996-03-22 | 2000-06-27 | Астра Актиеболаг | Производные замещенного 1,2,3,4-тетрагидронафталина |
| WO2001090082A1 (en) * | 2000-05-25 | 2001-11-29 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718317A1 (de) * | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| CA1331191C (en) | 1988-03-25 | 1994-08-02 | Bengt Ronny Andersson | Therapeutically useful tetralin derivatives |
| FR2659323B1 (fr) | 1990-03-07 | 1992-06-12 | Synthelabo | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
| DE60114413T2 (de) | 2000-05-25 | 2006-07-27 | F. Hoffmann-La Roche Ag | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten |
| PL370799A1 (en) * | 2001-12-03 | 2005-05-30 | F.Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
-
2002
- 2002-11-25 PL PL02370799A patent/PL370799A1/xx not_active Application Discontinuation
- 2002-11-25 MX MXPA04005313A patent/MXPA04005313A/es active IP Right Grant
- 2002-11-25 AT AT02787797T patent/ATE381541T1/de not_active IP Right Cessation
- 2002-11-25 BR BR0214649-5A patent/BR0214649A/pt not_active IP Right Cessation
- 2002-11-25 EP EP02787797A patent/EP1453806B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60224221T patent/DE60224221T2/de not_active Expired - Lifetime
- 2002-11-25 AU AU2002352124A patent/AU2002352124A1/en not_active Abandoned
- 2002-11-25 JP JP2003549317A patent/JP4322675B2/ja not_active Expired - Fee Related
- 2002-11-25 WO PCT/EP2002/013219 patent/WO2003048125A1/en not_active Ceased
- 2002-11-25 ES ES02787797T patent/ES2297029T3/es not_active Expired - Lifetime
- 2002-11-25 KR KR1020047008423A patent/KR100668231B1/ko not_active Expired - Fee Related
- 2002-11-25 CA CA2469055A patent/CA2469055C/en not_active Expired - Fee Related
- 2002-11-25 CN CNB028240170A patent/CN100358870C/zh not_active Expired - Fee Related
- 2002-11-25 RU RU2004120558/04A patent/RU2311408C2/ru not_active IP Right Cessation
- 2002-12-02 US US10/308,092 patent/US6635658B2/en not_active Expired - Fee Related
- 2002-12-02 AR ARP020104638A patent/AR037611A1/es not_active Application Discontinuation
-
2003
- 2003-06-27 US US10/608,604 patent/US6806278B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU98119276A (ru) * | 1996-03-22 | 2000-06-27 | Астра Актиеболаг | Производные замещенного 1,2,3,4-тетрагидронафталина |
| WO1998000412A1 (en) * | 1996-07-01 | 1998-01-08 | Schering Corporation | Muscarinic antagonists |
| WO1998001425A1 (en) * | 1996-07-10 | 1998-01-15 | Schering Corporation | 1,4-di-sustituted piperidines as muscarinic antagonists |
| WO2001090082A1 (en) * | 2000-05-25 | 2001-11-29 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE381541T1 (de) | 2008-01-15 |
| DE60224221T2 (de) | 2008-12-11 |
| US20030171362A1 (en) | 2003-09-11 |
| JP2005518368A (ja) | 2005-06-23 |
| ES2297029T3 (es) | 2008-05-01 |
| US6806278B2 (en) | 2004-10-19 |
| CN100358870C (zh) | 2008-01-02 |
| BR0214649A (pt) | 2004-11-03 |
| CA2469055A1 (en) | 2003-06-12 |
| PL370799A1 (en) | 2005-05-30 |
| KR20050044641A (ko) | 2005-05-12 |
| WO2003048125A1 (en) | 2003-06-12 |
| CA2469055C (en) | 2011-03-29 |
| RU2004120558A (ru) | 2005-07-20 |
| EP1453806A1 (en) | 2004-09-08 |
| US20040092604A1 (en) | 2004-05-13 |
| KR100668231B1 (ko) | 2007-01-16 |
| EP1453806B1 (en) | 2007-12-19 |
| CN1639124A (zh) | 2005-07-13 |
| MXPA04005313A (es) | 2004-09-13 |
| AR037611A1 (es) | 2004-11-17 |
| JP4322675B2 (ja) | 2009-09-02 |
| DE60224221D1 (de) | 2008-01-31 |
| US6635658B2 (en) | 2003-10-21 |
| AU2002352124A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102325753B (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| RU2320657C2 (ru) | Новые производные пирролидиния | |
| JP5572157B2 (ja) | Ｎｏｓ阻害活性を有するベンゾオキサジン類、ベンゾチアジン類、および関係化合物 | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| CN110177551B (zh) | 脂质合成的杂环调节剂 | |
| UA72611C2 (uk) | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази | |
| RU2002133220A (ru) | Замещенные 1-аминоалкиллактамы и их применение в качестве антагонистов мускариновых рецепторов | |
| CN102791697A (zh) | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 | |
| JP2009504764A5 (enExample) | ||
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| JP2016539144A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| HU229074B1 (en) | Tricyclic benzodiazepines as vasopressin receptor antagonists | |
| WO2014151784A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2022025116A (ja) | 抗菌性化合物 | |
| CN114409656B (zh) | Pim激酶抑制剂 | |
| CN106715440A (zh) | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 | |
| CN101541806A (zh) | 用作血管升压素拮抗剂的螺环苯并氮杂 | |
| CN115667236B (zh) | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 | |
| ES2666188T3 (es) | Antagonistas del v1a de vasopresina beta-lactámicos | |
| JP2004507527A5 (enExample) | ||
| CN104487076A (zh) | 用于治疗细菌感染的方法和组合物 | |
| JP2009501745A5 (enExample) | ||
| JP2008538583A5 (enExample) | ||
| RU2007102226A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081126 |